ESMO 2016: Press Conference Programme

We invite all media representatives to attend the daily press conferences, which will be held during ESMO 2016

Venue: Press Conference Room
Bella Center, Copenhagen, Denmark

Download the ESMO 2016 Press Conference Programme

Press Conference Schedule & Programme*

Opening Press Conference: Friday, 7 October, 10:30-11:30

Moderator: Solange Peters

• Prof Solange Peters, Chair ESMO Press Committee: Overview of ESMO Press Programme
• Prof Ulrik Lassen, ESMO Local Officer Denmark
• Andrés Cervantes, Chair ESMO 2016 Scientific Programme: Scientific Programme Highlights
• Dr Lidija Kandolf-Sekulovic: 13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe
• Prof Josep Tabernero, ESMO President Elect: ESMO initiatives for equal access to treatment
• Prof Fortunato Ciardiello, ESMO President: ESMO vision for integrated care
• Prof Solange Peters: Q&A

Press Conference 1: Saturday, 8 October 2016 , 08:15-09:00

 Moderator: Evandro De Azambuja

• LBA1_PR: First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Monaleesa 2. Gabriel Hortobagyi
• LBA2_PR: Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Alexander Eggermont
• LBA3_PR: A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). Mansoor Raza Mirza

Press Conference 2: Sunday, 9 October 2016, 08:15-09:00

Moderator: Stefan Zimmermann

• LBA8_PR: KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%. Martin Reck
• LBA42_PR: Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study.  Giorgio Scagliotti
• LBA44_PR: Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC. Fabrice Barlesi
• LBA 2949_PR: Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: Keynote-021 cohort g. Corey Langer 

Press Conference 3: Monday, 10 October, 08:15-09:00

Moderator: Dirk Arnold

• LBA9_PR: Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). Karim Fizazi
• LBA11_PR: Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) Alain Ravaud
• LBA30_PR: CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. Toni Choueiri
• LBA6_PR: Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. Alessandro Gronchi

Congress highlights. Q&A for Press: Tuesday, 11 October, 08:15-9:00

• Prof Solange Peters, Chair ESMO Press Committee
• Prof Andrés Cervantes, Chair ESMO 2016 Scientific Programme

*Subject to changes